{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:35:35Z","timestamp":1793208935379,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":124,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cytokinetics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Treatment with aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) led to significant improvements in patient-reported outcomes (PROs) in the pivotal SEQUOIA-HCM trial over 24 weeks, but its longer-term impact has not been described. The aim of this study was to describe the long-term effects of aficamten across multiple PROs in FOREST-HCM, an open-label extension study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>Participants with oHCM completing an aficamten trial were offered enrolment in FOREST-HCM. The Kansas City Cardiomyopathy Questionnaire (KCCQ), Seattle Angina Questionnaire 7-item, EuroQol Five-Dimensional Questionnaire index, and visual analogue scale were administered at baseline and at weeks 12, 24, 36, and 48. Associations among PROs and clinical markers of oHCM severity were assessed with Spearman correlation coefficients. A total of 172 participants (mean age 60.4 [SD \u00b1 13.1] years; 45.3% female) completed \u226548 weeks of follow-up as of 31 August 2024, and were included. Significant improvements in all PROs were observed by week 12 and sustained through week 48. At 48 weeks, mean Kansas City Cardiomyopathy Questionnaire\u2013Overall Summary Score improved by 18.8 (16.9\u201320.6) points, (P &amp;lt; .001), with the largest gains in the KCCQ Quality of Life domain (25.8 points [23.2\u201328.5; P &amp;lt; .001]). Seattle Angina Questionnaire 7-item -Summary Scores increased by 17.2 (15.1\u201319.4; P &amp;lt; .001), and EuroQol Five-Dimensional Questionnaire index and visual analogue scale scores improved by 0.11 and 12.7 points, respectively (P &amp;lt; .001). Improvements in PROs were significantly correlated with important clinical measures of oHCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aficamten resulted in sustained improvements across multiple health status dimensions, which also correlated with clinical markers of oHCM severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>NCT04848506<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag244","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:50:41Z","timestamp":1785498641000},"page":"819-830","source":"Crossref","is-referenced-by-count":1,"title":["Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM"],"prefix":"10.1093","volume":"28","author":[{"given":"Shepard D","family":"Weiner","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , 173 Fort Washington Avenue, New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusha W","family":"Liang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , 173 Fort Washington Avenue, New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Oregon Health and Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3411-1334","authenticated-orcid":false,"given":"Theodore P","family":"Abraham","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-3487","authenticated-orcid":false,"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[{"name":"Inherited Cardiovascular Diseases Unit, Complejo Hospitalario Universitario de A Coru\u00f1a, INIBIC, CIBERCV-ISCIII , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Cooper","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Liverpool John Moores University , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Inherited Cardiovascular Disease Unit, Barts Heart Centre and University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"de Feria","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S","family":"Maron","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Lahey Hospital and Medical Center , Burlington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Oreziak","sequence":"additional","affiliation":[{"name":"National Institute of Cardiology , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Michigan Medical Center , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Spertus","sequence":"additional","affiliation":[{"name":"University of Missouri\u2014Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albree","family":"Tower-Rader","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Butzner","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Godown","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Heitner","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-1287","authenticated-orcid":false,"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady I","family":"Malik","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Melloni","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyrell J","family":"Simkins","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wei","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Nassif","sequence":"additional","affiliation":[{"name":"University of Missouri\u2014Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali T","family":"Owens","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026102813123021300_xuag244-B1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2026102813123021300_xuag244-B2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026102813123021300_xuag244-B3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrcardio.2011.159","article-title":"Mechanisms of disease: hypertrophic cardiomyopathy","volume":"9","author":"Frey","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026102813123021300_xuag244-B4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026102813123021300_xuag244-B5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026102813123021300_xuag244-B6","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026102813123021300_xuag244-B7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cardfail.2024.04.024","article-title":"Evolving strategies for the management of obstructive hypertrophic cardiomyopathy","volume":"30","author":"Liang","year":"2024","journal-title":"J Cardiac Fail"},{"key":"2026102813123021300_xuag244-B8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2026102813123021300_xuag244-B9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026102813123021300_xuag244-B10","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102813123021300_xuag244-B11","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102813123021300_xuag244-B12","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"2026102813123021300_xuag244-B13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.jacc.2024.08.014","article-title":"Effect of aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","volume":"84","author":"Sherrod","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102813123021300_xuag244-B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026102813123021300_xuag244-B15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102813123021300_xuag244-B16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026102813123021300_xuag244-B17","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026102813123021300_xuag244-B18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026102813123021300_xuag244-B19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1161\/CIRCOUTCOMES.114.000967","article-title":"Development and validation of a short version of the Seattle Angina Questionnaire","volume":"7","author":"Chan","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026102813123021300_xuag244-B20","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2026102813123021300_xuag244-B21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.5603\/KP.a2018.0033","article-title":"EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature","volume":"76","author":"Bat\u00f3g","year":"2018","journal-title":"Kardiol Pol"},{"key":"2026102813123021300_xuag244-B22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","article-title":"Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores","volume":"20","author":"McClure","year":"2017","journal-title":"Value Health"},{"key":"2026102813123021300_xuag244-B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102217","article-title":"Changing health related quality of life and outcomes in heart failure by age, sex and subtype","volume":"64","author":"Lawson","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026102813123021300_xuag244-B24","volume-title":"ECDEU Assessment Manual for Psychopharmacology Revised, 1976","author":"Guy","year":"1976"},{"key":"2026102813123021300_xuag244-B25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pcad.2023.08.007","article-title":"Patient-reported outcomes in clinical studies of patients with hypertrophic cardiomyopathy","volume":"80","author":"Reza","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"2026102813123021300_xuag244-B26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.cardfail.2024.09.019","article-title":"The rise of patient-reported outcome measures: trends in heart failure clinical trials","volume":"31","author":"Khan","year":"2025","journal-title":"J Card Fail"},{"key":"2026102813123021300_xuag244-B27","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"2026102813123021300_xuag244-B28","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026102813123021300_xuag244-B29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jamacardio.2018.3359","article-title":"Association of transcatheter mitral valve repair with quality of life outcomes at 30 days and 1 year: analysis of the Transcatheter Valve Therapy Registry","volume":"3","author":"Arnold","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026102813123021300_xuag244-B30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCHEARTFAILURE.112.970053","article-title":"Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis","volume":"6","author":"Arnold","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026102813123021300_xuag244-B31","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/ejhf.3263","article-title":"Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced\/preserved ejection fraction","volume":"26","author":"Yang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102813123021300_xuag244-B32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"141","author":"Hanna","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026102813123021300_xuag244-B33","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102813123021300_xuag244-B34","doi-asserted-by":"publisher","author":"Nguyen","DOI":"10.1101\/2025.09.15.25335783"},{"key":"2026102813123021300_xuag244-B35","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00392-024-02496-1","article-title":"Incidence and recurrence of atrial fibrillation among patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: a single-center experience","volume":"115","author":"Liang","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026102813123021300_xuag244-B36","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten","volume":"21","author":"Castrichini","year":"2024","journal-title":"Heart Rhythm"},{"key":"2026102813123021300_xuag244-B37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacep.2024.10.014","article-title":"Atrial fibrillation in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: real-world incidence, management, and outcomes","volume":"11","author":"Boyle","year":"2025","journal-title":"JACC Clin Electrophys"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag244\/70461198\/xuag244.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/819\/70461198\/xuag244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/819\/70461198\/xuag244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:12:40Z","timestamp":1793207560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/4\/819\/8749450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag244","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]}}}